The INRG Classification System, which was based on the analysis of over 8,800 patients, was established to advance treatment for children with neuroblastoma diagnosed around the world through international collaboration. The INRG Task Force recognized the potential value of this large patient cohort, and a process was developed to make the data available to the neuroblastoma research community. More than 20 research studies have been conducted, including a number of seminal studies analyzing rare cohorts, never before possible. In an effort to integrate genomic data, we have recently we transformed the original flat-file database into a queryable web-based format that is able to link to other databases (ie, the iINRGdb). We have also substantially expanded the clinical cohort in the iINRGdb, which now contains data on more than 17,800 patients. In addition, a cohort discovery tool has been built and is available to the public (http://inrgdb.org). Governance of data contribution and access is being refined, and an international effort is ongoing to catalogue and link existing neuroblastoma genomic. Germline genotype data generated in the Maris laboratory at the Children’s Hospital of Philadelphia and array comparative genomic hybridization (CGH) data generated from patients enrolled on the SIOPEN infant trial are currently linked to the clinical cohort and are available to investigators for analysis. Genomic data generated through the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project will be linked in the near future. The iINRGdb will provide an unparralled resource to enable a deeper our understanding of the epidemiology of neuroblastoma, expand our knowledge regarding the pathways that drive malignant growth and treatment resistance, and may ultimately lead to more effective, individualized therapies.